Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Clinical Lung Cancer
|
December 31, 2023
Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer
Paola Ghanem, Joseph C Murray, Melinda Hsu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 5, 2025
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan
Hope Rugo, Aditya Bardia, Debora S Bruno, et al.
The Patient
|
August 22, 2018
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
Suzanne McMullen, Lisa M Hess, Edward S Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline
Bryan J Schneider, Nofisat Ismaila, Joachim Aerts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial
Benjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer
Benjamin Levy, Alexander Spira, Daniel Becker, et al.
Oral Oncology
|
January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Antonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Clinical Lung Cancer
|
December 31, 2023
Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer
Paola Ghanem, Joseph C Murray, Melinda Hsu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
Martin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
August 5, 2025
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan
Hope Rugo, Aditya Bardia, Debora S Bruno, et al.
The Patient
|
August 22, 2018
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
Suzanne McMullen, Lisa M Hess, Edward S Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline
Bryan J Schneider, Nofisat Ismaila, Joachim Aerts, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial
Benjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Caroline E McCoach, Collin M Blakely, Kimberly C Banks, et al.
Page
of 8